Evidence map›Paper›PMID 42251027›Full record

ArticleNPJ Parkinson's disease2026

Plasma neurofilament light chain in early Parkinson's disease predicts motor complications: a prospective cohort study.

Ningning Che, Jingxuan Huang, Shichan Wang, Qirui Jiang, Tianmi Yang, Yi Xiao, Ruwei Ou, Chunyu Li, Huifang Shang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ Parkinson's disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ningning Che *Department of Neurology, Laboratory of Neurodegenerative Disorders, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Jingxuan Huang *Department of Neurology, Laboratory of Neurodegenerative Disorders, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Shichan WangDepartment of Neurology, Laboratory of Neurodegenerative Disorders, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Qirui JiangDepartment of Neurology, Laboratory of Neurodegenerative Disorders, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Tianmi YangDepartment of Neurology, Laboratory of Neurodegenerative Disorders, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Yi XiaoDepartment of Neurology, Laboratory of Neurodegenerative Disorders, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Ruwei OuDepartment of Neurology, Laboratory of Neurodegenerative Disorders, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Chunyu LiDepartment of Neurology, Laboratory of Neurodegenerative Disorders, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Huifang ShangDepartment of Neurology, Laboratory of Neurodegenerative Disorders, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, Sichuan, China. hfshang2002@126.com.

Funding

National Key Research and Development Program of China 2021YFC251200the Sichuan Science and Technology Program 2022ZDZX0023
6 · The paper itself

Abstract

Whether blood biomarkers can predict the development of motor complications in early-stage Parkinson's disease (PD) remains unclear. In this prospective longitudinal cohort study, 173 patients with early-stage PD were followed for up to seven years. Plasma neurofilament light chain (NfL), glial fibrillary acidic protein (GFAP), phosphorylated tau181 (p-tau181), amyloid beta 42 (Aβ42), and amyloid beta 40 (Aβ40) were measured at baseline, 1-year, and 2-year follow-up using an ultrasensitive single-molecule array platform. Kaplan-Meier and Cox regression analyses were performed to identify predictors of motor fluctuations and dyskinesias. Motor fluctuations and dyskinesias occurred in 41.6% and 17.9% of participants, respectively. Patients who developed motor complications had higher baseline plasma NfL, GFAP, and Aβ40 levels. However, after adjustment for confounders, only higher baseline NfL independently predicted the future development of motor complications, whereas longitudinal changes in plasma biomarkers were not associated with these outcomes. Higher baseline levodopa daily dose and greater anxiety and depression scores were also identified as clinical predictors. These findings suggest that plasma NfL may serve as a minimally invasive biomarker for early risk stratification of motor complications in PD.

Identifiers

PMID42251027
PMCPMC13578695

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.